Get the Stockscreener App
1.36
0.00%
0.00
Igm Biosciences Inc stock is traded at $1.36, with a volume of 195.93K.
It is up +0.00% in the last 24 hours and up +7.09% over the past month.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
See More
Previous Close:
$1.36
Open:
$1.36
24h Volume:
195.93K
Relative Volume:
1.13
Market Cap:
$81.16M
Revenue:
$2.91M
Net Income/Loss:
$-220.40M
P/E Ratio:
-0.3736
EPS:
-3.64
Net Cash Flow:
$-176.15M
1W Performance:
+0.00%
1M Performance:
+7.09%
6M Performance:
-34.93%
1Y Performance:
-85.38%
1-Day Range:
$1.35
$1.36
1-Week Range:
$1.33
$1.38
52-Week Range:
$0.92
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
Name
Igm Biosciences Inc
Sector
Industry
Phone
650-965-7873
Address
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
Compare IGMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGMS
Igm Biosciences Inc
|
1.36 | 81.16M | 2.91M | -220.40M | -176.15M | -3.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-10-25 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-10-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-10-25 | Downgrade | Stifel | Buy → Hold |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-01-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-24 | Downgrade | Truist | Buy → Hold |
| Feb-09-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-22 | Resumed | Jefferies | Buy |
| Oct-17-22 | Initiated | JP Morgan | Neutral |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Dec-13-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-21 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-26-21 | Initiated | Morgan Stanley | Overweight |
| Jan-29-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-22-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-17-20 | Initiated | Robert W. Baird | Outperform |
| Jul-01-20 | Initiated | H.C. Wainwright | Buy |
| May-28-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Wedbush | Outperform |
| Oct-14-19 | Initiated | Guggenheim | Buy |
| Oct-14-19 | Initiated | Jefferies | Buy |
| Oct-14-19 | Initiated | Piper Jaffray | Overweight |
| Oct-14-19 | Initiated | Stifel | Buy |
View All
Igm Biosciences Inc Stock (IGMS) Latest News
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
IGM Biosciences price target lowered to $1 from $2 at Truist - Yahoo Finance
Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech
IGM Biosciences Faces Nasdaq Non-Compliance Notice - TipRanks
Truist Revises IGM Biosciences (IGMS) Price Target to $1 | IGMS Stock News - GuruFocus
Truist Cuts Price Target on IGM Biosciences to $1 From $2, Keeps Hold Rating - MarketScreener
IGM Biosciences (NASDAQ:IGMS) Cut to "Sell" at Wall Street Zen - MarketBeat
Millennium Management LLC Sells 69,074 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
Two Sigma Investments LP Grows Position in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Rating Lowered to “Sell” at Wall Street Zen - Defense World
IGM Biosciences, Inc. (NASDAQ:IGMS) Given Consensus Rating of "Reduce" by Brokerages - MarketBeat
IGM Biosciences (NASDAQ:IGMS) Stock Rating Upgraded by Wall Street Zen - MarketBeat
IGM Biosciences Reports Increased Net Loss Amid Strategic Focus - TipRanks
Wall Street Zen Upgrades IGM Biosciences (NASDAQ:IGMS) to “Hold” - Defense World
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of “Reduce” from Analysts - Defense World
IGM Biosciences Terminates Headquarters Lease Agreement - TipRanks
IGM Biosciences, Inc. (NASDAQ:IGMS) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
IGM Biosciences earnings missed by $0.51, revenue fell short of estimates - Investing.com Canada
Sanofi Invests $8.79 Million in IGM Biosciences, Inc. (NASDAQ:IGMS) - MarketBeat
Rheumatoid Arthritis Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH - The Globe and Mail
IGM Biosciences’ SWOT analysis: biotech stock faces pivotal moment By Investing.com - Investing.com Nigeria
IGM Biosciences’ SWOT analysis: biotech stock faces pivotal moment - Investing.com
30,148 Shares in IGM Biosciences, Inc. (NASDAQ:IGMS) Bought by Cubist Systematic Strategies LLC - Defense World
IGM Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates - MSN
IGM Biosciences (IGMS) to Release Earnings on Wednesday - MarketBeat
IGM Biosciences (IGMS) to Release Quarterly Earnings on Wednesday - Defense World
IGM Biosciences says it is dropping development of imvotamab - The Pharma Letter
Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures - Fierce Biotech
IGM Biosciences ends agreement with Sanofi - Investing.com Australia
IGM Biosciences ends agreement with Sanofi By Investing.com - Investing.com South Africa
IGM Biosciences Ends Genzyme Collaboration, Cuts Workforce - TipRanks
Engineering an antibody against flu with sticky staying power - Ohio State News
Price T Rowe Associates Inc. MD Sells 445,260 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) - MarketBeat
Renaissance Technologies LLC Raises Stock Holdings in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Stock Price Down 1.5%Here's Why - MarketBeat
IGM Biosciences Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Igm Biosciences Inc Stock (IGMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Igm Biosciences Inc Stock (IGMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tahir Misbah | CHIEF FINANCIAL OFFICER |
Jun 16 '25 |
Sale |
1.20 |
1,522 |
1,825 |
178,802 |
| Harler Mary Beth | Chief Executive Officer |
Jun 16 '25 |
Sale |
1.20 |
1,522 |
1,825 |
338,181 |
| Decker Lisa Lynn | CHIEF BUSINESS OFFICER |
Jun 16 '25 |
Sale |
1.20 |
951 |
1,140 |
72,578 |
| Weber Steven | PRINCIPAL ACCOUNTING OFFICER |
May 14 '25 |
Sale |
1.12 |
1,865 |
2,090 |
27,016 |
| Weber Steven | PRINCIPAL ACCOUNTING OFFICER |
Mar 14 '25 |
Sale |
1.23 |
1,701 |
2,092 |
28,881 |
| Tahir Misbah | CHIEF FINANCIAL OFFICER |
Mar 14 '25 |
Sale |
1.23 |
7,329 |
9,015 |
180,324 |
| Harler Mary Beth | Chief Executive Officer |
Mar 14 '25 |
Sale |
1.23 |
7,329 |
9,015 |
339,703 |
| Decker Lisa Lynn | CHIEF BUSINESS OFFICER |
Mar 14 '25 |
Sale |
1.23 |
4,512 |
5,550 |
73,529 |
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):